Due to the Covid pandemic, The Department of Health and Human Services granted Emergent BioSolutions a $628 million contract under the Biomedical Advanced Research and Development Authority (BARDA), a U.S. federal agency that funds disease-fighting technology in efforts to increase the manufacturing capacity for vaccine development for COVID-19. Emergent BioSolutions has committed to manufacturing COVID-19 vaccine candidates through 2021, including Johnson & Johnson, Novavax Inc, and Vaxart. 

Read more here

More on: